Based on the argument that hyperglutamatergic state contributes to the development of several neurological and psychiatric diseases, decrease in GLT-1 and xCT expression can lead to hyperglutamatergic state, and upregulating these transporters by the β-lactam antibiotic CEF, known to upregulate GLT-1 and xCT, could be a potential pharmacological approach to attenuate glutamate dysregulation (Rothstein et al., 2005; Sari et al., 2011; Das et al., 2015). Here, SLC7A11 is linked to psychiatric disorder.